Study to compare ropivacaine and bupivacaine for lower abdomen and lower limb surgeries under spinal anaesthesia.

A comparative study of 0.75% hyperbaric ropivacaine versus 0.5% hyperbaric bupivacaine for lower abdomen and lowerlimb surgeries under spinal anaesthesia - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057269

Enrollment

124

Registered

2023-09-06

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K402- Bilateral inguinal hernia, withoutobstruction or gangrene Health Condition 2: N813- Complete uterovaginal prolapse Health Condition 3: N430- Encysted hydrocele Health Condition 4: S820- Fracture of patella Health Condition 5: S821- Fracture of upper end of tibia Health Condition 6: K409- Unilateral inguinal hernia, without obstruction or gangrene

Interventions

Intervention1: ROPIVACAINE: 0.75% hyperbaric Ropivacaine 3ml (22.5mg)in lower abdomen and lower limb surgeries under spinal anaesthesia in a study conducting in 6 months Control Intervention1: BUPIVAC

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing lower abdomen surgeries giving consent to participate in study. Age between 18 to 65 years. Body weight between 45 to 70 kg. ASA grade I and II

Exclusion criteria

Exclusion criteria: Patients refusal ASA grade III and IV Patients with severe respiratory, cardiovascular, renal diseases, obesity Infection Coagulopathy Spinal deformity Allergic to local anaesthetic drugs History of seizure and neurological deficit Age below 18 years and above 65 years weight below 45kg and above 70 kg

Design outcomes

Primary

Measure	Time frame
Expected more hemodynamic stability in 0.75% Ropivacaine compared to bupivacaine during spinal anaesthesia intraoperatively & post operativelyTimepoint: 24 hours	—

Secondary

Measure	Time frame
Expected better cardiac stability in 0.75% Ropivacaine than BupivacaineTimepoint: 24 hours;expected early sensory & motor block in 0.75 % Ropivacaine than BupivacaineTimepoint: 24 hours;Expected faster recovery early mobilization & micturition in Ropivacaine compared to bupivacaineTimepoint: 24 hours	—

Countries

India

Contacts

Public ContactDr Kavya Kanjikkal

Gajra Raja Medical College

drpreetiravigoyal@gmail.com9424455330

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026